Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RLY-1971 in advanced solid tumors
NCT04252339Phase 1Completed
- Sponsor
- Roche
- Start
- Feb 2020
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of migoprotafib in solid tumor, sponsored by Roche. Primary endpoints: Maximum Tolerated Dose and Recommended Phase 2 Dose. Started Feb 2020; status: completed.
02
Drugs
migoprotafib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04252339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04252339.